Research programme: anti-infectives - GlaxoSmithKline/Valneva

Drug Profile

Research programme: anti-infectives - GlaxoSmithKline/Valneva

Latest Information Update: 17 Mar 2015

Price : $50

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Antibodies; Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Viral infections

Most Recent Events

  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 02 Jul 2007 Preclinical trials in Bacterial infections in Austria (unspecified route)
  • 02 Jul 2007 Preclinical trials in Hepatitis C prevention in Austria (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top